Insider Buying: AstraZeneca (LON:AZN) Insider Buys 2,500 Shares of Stock

AstraZeneca PLC (LON:AZN) insider Michel Demare purchased 2,500 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average price of £121.21 per share, with a total value of £303,025.

AstraZeneca Stock Down 0.5%

Shares of AZN traded down GBX 64 during midday trading on Tuesday, reaching £120.90. 71,305,945 shares of the company were exchanged, compared to its average volume of 32,175,939. The stock has a 50-day moving average price of £122.84 and a 200-day moving average price of £135.11. The company has a market cap of £187.50 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 0.86 and a beta of 0.20. AstraZeneca PLC has a 1-year low of £107.84 and a 1-year high of £157.32. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £117 target price on shares of AstraZeneca in a research report on Tuesday. Royal Bank Of Canada reiterated an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a research note on Tuesday, September 8th. Jefferies Financial Group restated a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Wednesday, September 9th. Citigroup raised their target price on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Finally, Berenberg Bank dropped their price objective on shares of AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a report on Tuesday. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of £150.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.